ENSIKLOPEDIA Cari Tekan Enter untuk memulai pencarian cepat. Kembali ke Ensiklopedia Arsip Wikipedia Indonesia Ruplizumab RuplizumabMonoclonal antibody Pharmaceutical compoundRuplizumabMonoclonal antibodyTypeWhole antibodySourceHumanized (from mouse)TargetCD154Clinical dataTrade namesAntovaATC codenoneIdentifiersCAS Number220651-94-5 NChemSpidernoneUNII562JQF15GN NY (what is this?) (verify) Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2] References ↑ Liossis SN, Sfikakis PP (2004). "Costimulation blockade in the treatment of rheumatic diseases". BioDrugs. 18 (2): 95–102. doi:10.2165/00063030-200418020-00003. PMID 15046525. S2CID 24762590. ↑ Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, Kaburaki J, et al. (February 2006). "Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism". Rheumatology. 45 (2): 150–6. doi:10.1093/rheumatology/kei118. PMID 16188945. vteImmunosuppressive drugs / Immunosuppressants (L04)Intracellular(initiation)Antimetabolites purine synthesis inhibitors Azathioprine Mycophenolic acid dihydroorotate dehydrogenase inhibitors Leflunomide Teriflunomide antifolate Methotrexate Macrolides/other IL-2 inhibitors FKBP/Cyclophilin/Calcineurin Ciclosporin Pimecrolimus Tacrolimus Voclosporin Abetimus Gusperimus IMiDs Lenalidomide Pomalidomide Thalidomide PDE4 inhibitor Apremilast JAK inhibitors Baricitinib Deucravacitinib Deuruxolitinib Filgotinib Itacitinib Peficitinib Ritlecitinib Tofacitinib Upadacitinib Intracellular(reception)IL-1 receptor antagonists Anakinra mTOR Everolimus Ridaforolimus Sirolimus Temsirolimus Umirolimus Zotarolimus ExtracellularAntibodiesMonoclonalSerum target(noncellular) Complement component 5 Eculizumab Ravulizumab TNF Adalimumab Afelimomab Certolizumab pegol Golimumab Infliximab Nerelimomab Interleukin Anakinra Basiliximab Bimekizumab Briakinumab Brodalumab Canakinumab Daclizumab Netakimab Olokizumab Sarilumab Satralizumab Secukinumab Siltuximab Sirukumab Spesolimab Tocilizumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12, IL-13, and IL-23 Guselkumab Lebrikizumab Risankizumab Tildrakizumab Ustekinumab IL-17A Ixekizumab Secukinumab Cellulartarget CD3 Muromonab-CD3 Otelixizumab Teplizumab Visilizumab CD4 Clenoliximab Keliximab Zanolimumab CD11a Efalizumab CD18 Erlizumab CD20 Obinutuzumab Ocrelizumab (+hyaluronidase) Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin Aselizumab CD80 Galiximab CD147/Basigin Gavilimomab CD154 Frexalimab Ruplizumab BLyS Belimumab CAT Bertilimumab Lerdelimumab Metelimumab Integrin Natalizumab Vedolizumab Interleukin-6 receptor Tocilizumab LFA-1 Odulimomab IL-2 receptor/CD25 Basiliximab Daclizumab Inolimomab T-lymphocyte (Zolimomab aritox) Unsorted Alemtuzumab Anifrolumab Atorolimumab Batoclimab Begelomab Bimekizumab Briakinumab Brodalumab Canakinumab Cedelizumab Crovalimab Divozilimab Emapalumab Fontolizumab Inebilizumab Ixekizumab Maslimomab Morolimumab Nipocalimab Ofatumumab Olokizumab Pexelizumab Reslizumab Risankizumab Rovelizumab Rozanolixizumab Sarilumab Satralizumab Seniprutug Sibeprenlimab Siltuximab Siplizumab Sirukumab Spesolimab Sutimlimab Talizumab Telimomab aritox Teprotumumab Vapaliximab Vepalimomab Polyclonal Anti-thymocyte globulin Anti-lymphocyte globulin -cept (Fusion) CTLA-4 Abatacept Belatacept TNF inhibitor Etanercept Opinercept Aflibercept Alefacept Rilonacept Telitacicept Unsorted Avacopan Belumosudil Blisibimod Cladribine Danicopan Darvadstrocel Difamilast Dimethyl fumarate Diroximel fumarate Efgartigimod alfa (+hyaluronidase) Etrasimod Fingolimod Imlifidase Iptacopan Nerandomilast Ozanimod Pegcetacoplan Pirfenidone Ponesimod Remibrutinib Siponimod Tegomil fumarate Tolebrutinib vteMonoclonal antibodies for the immune systemImmune systemHuman Immunosuppression: Abrilumab Adalimumab# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab Mouse Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox Chimeric Andecaliximab† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab Humanized Immunosuppressive: Apolizumab§ Aselizumab Atezolizumab Benralizumab Camrelizumab† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab‡ Epratuzumab Erlizumab Etrolizumab† Fontolizumab Frexalimab† Inebilizumab Itolizumab Lampalizumab† Letolizumab Ligelizumab† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§ Immune activation: Dostarlimab Other: Ibalizumab Chimeric + humanized Otelixizumab Rozanolixizumab Sutimlimab InterleukinHuman Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab Humanized Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab† Lebrikizumab Olokizumab† Perakizumab Risankizumab Spesolimab Tildrakizumab Veterinary Lokivetmab Inflammatory lesionsMouse Besilesomab Fanolesomab‡ Lemalesomab Sulesomab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information.vte This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.vte
